title: Can nitric oxide-based therapy prevent bronchopulmonary dysplasia?
abstract: A growing understanding of endogenous nitric oxide (NO) biology is helping to explain how and when exogenous NO may confer benefit or harm; this knowledge is also helping to identify new better-targeted NO-based therapies. In this review, results of the bronchopulmonary dysplasia clinical trials that used inhaled NO in the preterm population are placed in context, the biologic basis for novel NO therapeutics is considered, and possible future directions for NO-focused clinical and basic research in developmental lung disease are identified.
authors.affiliation: Division of Neonatology, Department of Pediatrics, Rainbow Babies & Children's Hospital, Case Medical Center/University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106-6010, USA.
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Raffay
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Martin
authors.forename: James D
authors.initials: JD
authors.lastname: Reynolds
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D001997:Bronchopulmonary Dysplasia / Q000517:prevention & control*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D009569:Nitric Oxide / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic
chemical_list: D009569:Nitric Oxide